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I. HEMATOPOIETIC STEM CELLS: IN VITRO 
ASSAYSANDREGULATORYFACTORS 
The production of mature blood cells is finely regulated, 
so that the homeostasis can be maintained and cell production 
be adapted to the specific needs of particular blood cell com- 
partments (e.g., granulocytes during infection). A complex 
regulatory network of positive and negative signals and cellular 
interactions serves the hematopoietic system to fulfill this role. 
In vitro colony assays are powerful tools for studies that aim 
at the recognition of hematopoietic progenitor cells of distinct 
differentiation pathways and at different levels of maturation. 
These assays have also been used to define the complex role 
of hematopoietic growth factors in normal hematopoiesis. The 
same technology is currently being applied for elucidating 
growth factor responses of neoplastic clonogenic cells in he- 
matopoietic disease. 
An in vitro colony assay for primitive multilineage he- 
matopoietic precursor cells of both rodents and humans with 
the capacity to form granulocytic cells, macrophages, eryth- 
rocytes, megakaryocytes, collectively designated as CFU- 
GEMM, has been developed. I-3 Somewhat more mature pro- 
genitor cells that are committed to one hematopoietic lineage 
can be assayed in vitro as erythroid burst-forming units (BFU- 
E),4.5 erythroid colony-forming units (CFU-E),6 granulocyte/ 
monocyte CFU (CFU-GM),7.8 granulocyte CFU (CFU-G), 
monocyte CFU (CFU-M), eosinophil CFU (CFU-Eo), or mega- 
karyocyte CFU (CFU-Mega).’ Several regulatory molecules 
that induce colony formation from those precursor cells have 
been isolated following molecular cloning. 
In acute myeloid leukemia (AML), a transformed malig- 
nant precursor cell arises that is unable to generate terminally 
differentiated cells. This neoplastic cell population apparently 
escapes normal maturation impulses and expands aproportion- 
ally in marrow and blood. 
The technology of in vitro colony formation has been ap- 
plied to examine the proliferation and differentiation abilities 
of leukemic progenitor cells. In this review we discuss our 
understanding of leukemic blood cell formation in human AML, 
mainly based on the study of in vitro growth. 
II. RECOMBINANT HEMATOPOIETIC 
COLONY STIMULATING FACTORS 
The hematopoietic colony stimulating factors and their tar- 
get precursor cells are listed in Table 1. These glycoproteins 
regulate the proliferation and outgrowth of different hemato- 
poietic progenitors and frequently have a role in stimulating 
the metabolic and functional activities of the mature cell types 
as well. 
A. Human Multilineage Colony Stimulating Factor 
(Multi-CSF) or Interleukin3 (IL-3) 
Murine IL-3,38* also termed multi-CSF,4’ mast cell growth 
factor,“’ or stem cell activating factor,‘: is a stimulator of the 
proliferation of mouse in vivo multipotential stem cells (CFU- 
s) 39.4’ as well as the in vitro CFU-GEMM.“’ It has been sug- 
gested that murine IL-3 is also involved in the self-replication 
of pluripotent stem cells.4”.“1.44 The human homologue of multi- 
CSF/IL-3 has been cloned,“.” and was shown to stimulate the 
in vitro proliferation of normal bone marrow CFU-GEMM, 
BFU-E, and CFU-Eo. ” A direct stimulating effect of IL-3 upon 
myeloid progenitors was not apparent in vitro when auxiliary 
cells had been removed from hematopoietic progenitors before 
culture.” IL-3 improves the in vitro survival of CFU-G.” 
B. GM-CSF 
Granulocyte macrophage colony stimulating factor (GM- 
CSF) has effects on the function of granulocytes2Z.4s-47 and 
stimulates the proliferation of CFU-GEMM, BFU-E, and CFU- 
Eo in normal marrow.18-‘2~Z4~48 Human GM-CSF cDNA trans- 
ferred into COS cells produces a glycoprotein with a molecular 
weight of 19,000 to 22,00022~24 and into Escherichia coli a 
nonglycosylated molecule with a molecular weight of 16,000.i3 
Radioiodinated GM-CSF has been used to characterize mem- 
brane receptors on normal cells.49-s1 High-affinity (kDa 20 pM 
to 1 r&f) receptors for GM-CSF are abundantly expressed on- 
normal neutrophiis and eosinophils (500 to 4000 sites per cell). 
C. G-CSF and M-CSF 
Complementary DNA of the gene encoding for human G- 
CSF has been cloned and expressed in E. coli.“,30 G-CSF 
(recombinant) has a molecular weight of 18,800 Da. G-CSF 
stimulates granulocytic colonies from normal human marrow. 
It does not induce eosinophilic colony formation in vitro. 
cDNA encoding for human M-CSF, following expression, 
yields a mature protein of mol wt 26,000 to 45,000 Da de- 
pending on differences of posttranscriptional processing.32.33 
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Table 1 
Human Hematopoietic Growth Factors 
Cehdar sources 
Protein size Release activated 
Acronym NW Cell type by 
IL-3 14-28 T cells Mitogens 
GM-CSF 
G-CSF 
M-CSF 
EPO 
14-35 
18-22 
3545 
( x 2) 
18-26 
36 
T cells 
Endothelial 
cells 
Fibroblasts 
Monocytes 
Fibroblasts 
Endotbelial 
cells 
Monocytes 
Fibroblasts 
Endotbelial 
cells 
Kidney 
Liver 
Mitogens 
TNF, IL-1 
TNF, IL-I 
TNF, IL-l 
TPA, yIFN 
Hypoxia 
Low oxygen 
The biological activity on normal human hematopoietic cells 
is only scarcely defined. On the other hand, human M-CSF is 
a potent inducer of murine macrophage colonies in vitro. 
D. Erythropoietin 
Erythropoietin was purified following molecular cloning 
and expression in mammalian cells.35.36 Recombinant eryth- 
ropoietin (mol wt 36,000 glycosylated) stimulates BFU-E and 
CFU-E in vitro. 
III. HEMATOPOIESIS IN AML 
The malignantly transformed cell population expands pro- 
gressively when clinical AML evolves. In the marrow of AML 
patients immature cells, i.e., myeloblasts, predominate. Con- 
comitantly, normal hematopoiesis is suppressed, presumably 
by physical displacement of the normal stem cells by leukemic 
cells or inhibitory humoral factors (such as acidic isoferritins)52 
produced by the leukemic cells, leading to the characteristic 
anemia, thrombocytopenia, and leukopenia. 
Although AML is the result of clonal expansion of a single 
ce11,53 the resulting leukemic cell population is biologically 
heterogeneous as is evident from morphological, 3H-thymidine 
labeling ,54 immunological, cytogenetic, and colony culture 
studies. For instance, a small population of proliferating cells 
expressing self-renewal capacities can be identified among the 
AML cell mass in colony assays.55 
A. Techniques for AML Colony Growth 
In the initial attempts to grow leukemic colonies, normal 
leukocyte feeder cells were added to an agar underlayer as a 
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Hematowietic omenitor cell tamets 
Normal 
CFU-GEMM 
BFU-e 
CFU-EO 
CFU-GEMM 
BFLJ-e 
CFU-Eo 
Ref. Leukemia Ref. 
l&12 AML-CFU 13-17 
18-24 AML-CFU 14-17,25-28 
29-3 1 AML-CFU 14-17.28 
CFU-G 
CFIJ-M 32,33 AML-CFU 
(rare) 
14,16,34 
BFU-e 35,36 AML-CFU 14,37 
CFU-e (M-6 type) 
source of stimulating factors,56*57 and AML blast cells were 
plated in a second layer on top of the underlayer. The ap- 
pearance of leukemia-derived clones in these cultures has been 
confirmed by cytogenetic analysis.58 Other colony stimulating 
materials that were applied for in vitro growth of normal CFU- 
GM have also been employed for growing AML clonogenic 
cells, e.g., conditioned media from cell lines,59*6o human pla- 
cental-conditioned medium (HPCM),61 or phytohemagglutinin 
(PHA)-leukocyte-conditioned medium.62,63 
While these methods efficiently induce normal myeloid 
colony formation, they are often insufficient to permit the out- 
growth of AML colonies. In some cases, no or only single 
cells survive in the dish at the end of culture, indicating that 
no proliferation had occurred at a11.64-66 Frequently, small (less 
than 20 cells) or somewhat larger clusters (less than 40 cells) 
are produced during culture. Using standard culture techniques, 
the nongrowing and small cluster-forming groups of patients 
account for the majority (60 to 70%) of the newly diagnosed 
cases of AML.66.67 Seven-day colonies are composed of mor- 
phologically identifiable blast cells carrying cytogenetic AML 
markers. 
Attempts have been made to develop more efficient AML 
culture methods. Exposure of the cells to PHA during a 15-h 
preincubation in suspension and subsequent culturing in a soft 
agar dish with a leukocyte feeder allowed for the formation of 
significant numbers of AML colonies of more than 50 cells in 
the majority of patients with AML.‘O In subsequent modifi- 
cations of the technique, PHA was added directly to one-stage 
cultures that contained irradiated leukocytes in the agar un- 
derlayer and the AML target cells in a liquid overlayer,68*69 or 
PHA and HPCM in combination have been used as additions 
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to agar cultures.71 Others have employed PHA-leukocyte-con- 
ditioned medium as a stimulus in methylcellulose.62,72,73 These 
modified cultures are permissive to AML colony formation in 
80 to 90% of cases.55 However, the disadvantage of this type 
of assay is that the quantitative analysis of colony formation 
of leukemic cells can be hampered to a certain extent due to 
agglutination by PHA.7’ 
Thus the original colony culture techniques were based on 
the use of crude stimulating materials for growing AML-clon- 
ogenic cells, e.g., leukocyte feeder cells or conditioned media 
from cell lines, human placenta, or PHA-activated peripheral 
blood mononuclear cells.55 It has been shown that particularly 
T-lymphocytes and monocytes are the active subsets among 
the leukocyte feeder cells. 74 
Since the availability of pure growth factors, it has recently 
become possible to (1) understand the exact role of these hor- 
mones, either as individual or as combined activities in con- 
trolling the proliferation and differentiation of human AML 
cells and to identify possible abnormalities of AML growth in 
vitro and (2) standardize culture techniques for reproducible 
application in human AML, that is, with optimal concentrations 
of stimulators and without inhibitors. Therefore, in vitro studies 
are now undertaken to elucidate the complex system of growth 
factor regulation of human AML precursors. In this respect, 
the completely serum-free culture method for human AML 
cells, which was designed recently, appears a useful addition 
to the experimental arsenal.75 
8. Cell-Cell and Stroma-Cell Contact 
Several investigators ‘O.” have noted that the application of 
a liquid phase to the culture of AML cells results in more 
efficient cell growth and, conversely, that growth was inhibited 
in increasing concentrations of immobilizing methylcellu- 
lose.68,69 The fact that the cells could easily form small aggre- 
gates from which colony formation was initiated suggested that 
cell to cell contact may provide signals essential to AML cell 
growth in vitro. 7o The importance of cell-cell interactions is 
further supported by enhanced DNA synthesis that was seen 
when cell proliferative activity of AML blasts was evaluated 
in direct cell contact facilitating conditions in comparison to 
cell contact prohibitive circumstances.76 These comparisons 
were made under identical conditions, and an enhanced pro- 
liferative rate was positively related to the intensity of cell 
contact. Increased CSF concentrations in culture could not 
circumvent the dependence on cell-cell contact. Which mem- 
brane structures are involved in enhancement of AML prolif- 
eration in vitro is presently unknown. An analysis dealing with 
a possible role of the leukocyte function antigens (LFA), i.e., 
LFAl , Mac1 , ~150-95, did not provide evidence to indicate 
that these surface molecules are directly involved in the up- 
regulation of AML growth.16 
The importance of the marrow microenvironment for he- 
matopoietic function is evident from in vitro and in vivo studies 
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in rodents, but the role of the marrow stroma with respect to 
growth of human leukemia is largely elusive at the present 
time. It has been found that loss of leukemic proliferating cells 
occurs following cultivation upon stromal layers and that this 
loss is selective in comparison to normal hematopoietic stem 
cells.77 In CML, blast precursor cells were defective in their 
capacity to adhere to cultured stromal cells when compared 
with their normal marrow counterparts, and it was argued that 
alterations in cell surface properties of the cells may determine 
modified migration and maturation.78 The adhesive properties 
of the progenitor cells of human acute leukemia have not yet 
been examined in any reasonable detail. 
C. Cellular Heterogeneity 
The heterogeneous cellular composition of human AML 
may be regarded as a hierarchy of subpopulations of cells of 
different maturation stages.55.79 This concept is supported by 
immunological data that indicate that among AML blasts the 
in vitro colony forming cells (AML-CFU) carry immature sur- 
face phenotypes, while the immunophenotypically more ma- 
ture cells among the leukemia lack proliferative (i.e., colony 
forming) abilities.” Upon proliferation in vitro, colony forming 
cells give rise to maturing progeny, but maturation is incom- 
plete.63,81 Apparently the dynamics and negative relationships 
between proliferation and differentiation events characteristic 
of the normal hematopoietic system have to a certain extent 
been retained in human AML. It is difficult to determine the 
in vivo significance of AML-CFU. In vitro observations sup- 
port the idea that they function to maintain and expand the 
malignancy and indeed act as progenitor cells: (1) they have 
capacities for self-renewal,82-84 and (2) as normal hematopoietic 
precursors, they have the capacity not only to proliferate, but 
also to undergo some further differentiation in vitro.63~*1~85.86 
Immunologic analysis has shown that the phenotypes of 
AML-CFU vary markedly among patients with AML. In cer- 
tain cases, AML-CFU share immunologic features with CFU- 
GEMM cells, while in other instances AML-CFU express sur- 
face antigen combinations typical of committed granulocyte/ 
macrophage progenitors in normal bone marrow (CFU-GM).55 
Thus it has been appreciated that the immunological pheno- 
types of AML progenitors and particular types of normal he- 
matopoietic precursors are largely similar. However, detailed 
surface marker studies have revealed that discrepancies be- 
tween the immunologic surface phenotypes of AML-CFU and 
the majority normal marrow progenitors may exist. In one study 
that considered not only the presence or absence of antigenic 
determinants, but also marker density at the cell surface, dif- 
ferences between the immunophenotypes of AML-CFU from 
most of the normal hematopoietic progenitor cells were rec- 
ognized.87-89 Thus, frequently, the surface immunophenotypes 
of AML-CFU and the normal hematopoietic precursors are 
dissimilar. Crucial in these studies was that a combination of 
surface markers was selected that identified a constant surface 
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profile for CFU-GEMM, BFU-e, as well as day 7 CFU-GM 
and 14 CFU-GM and thus permitted the recognition of phen- 
otypes of AML-CFU at variance with these normal progenitors. 
Probably, these dominant progenitor phenotypes in AML re- 
flect those of infrequent, although essentially normal, hema- 
topoietic precursors that have expanded selectively in AML as 
a consequence of the abnormality of maturation. 
D. The Role of Colony Stimulating Factors in AYL 
Have AML cells become independent of CSFs, so that 
they will expand in a truly autonomous fashion? The answer 
to this question is probably no. In most cases of clinical AML, 
the cells show normal susceptibility to growth factor stimu- 
lation. IL-3 and GM-CSF, at usual concentrations, each as 
individual factors, induce colony formation in vifr~,‘~~~‘~~~ stim- 
ulate DNA synthesis,‘4~‘6 and enhance the survival of AML 
progenitors in vitro. I5 GM-CSF has also been shown to support 
the self-renewal of AML precursors.26 In addition to IL-3 and 
GM-CSF, G-CSF is successful in inducing AMP cell growth 
in culture at approximately similar frequency. Often, the same 
leukemias are susceptible to multiple CSFs. Each of these three 
CSFs as single factors is able to generate significant prolifer- 
ation in vitro. Infrequently, M-CSF induces AML growth in 
culture, and erythropoietin has occasionally been reported to 
act as a growth factor in human AML, i.e., in cases of eryth- 
roleukemia (M6).r4s3’ The fact that in certain cases of AML 
proliferation can be maximally stimulated in the presence of 
an impure PHA-leukocyte-conditioned medium leaves the pos- 
sibility open that yet other soluble growth factors operate in 
AML. 
The CSFs affect overlapping stages of the hematopoietic 
pathways and thus, to a significant extent, exert stimulating 
effects upon the same target cells. As yet, it remains unclear 
why it would be useful for the progenitor cells to be stimulable 
by more than one factor. Obviously, insight into the cooper- 
ative interactions between these molecules in controlling hu- 
man AML growth is of particular interest. 
In tritiated thymidine uptake assays it appeared that the 
responsiveness of AML cells to IL-3 parallels the response to 
GM-CSF.r4v16 This suggests that IL-3- and GM-CSF-respon- 
sive subpopulations of AML precursors to a certain extent 
overlap. Also it has become evident that usually IL-3 and GM- 
CSF do not produce additive proliferative effects, again sug- 
gesting that the two CSFs act mainly upon the same AML 
precursor cell subpopulation. In contrast, G-CSF produces ad- 
ditive growth-potentiating effects in certain cases of AML, 
when supplemented to cultures with IL-3 or GM-CSF. In col- 
ony culture, IL-3 has been shown to elevate colony numbers 
in a majority of AML cases when supplemented along with G- 
CSF or GM-CSF to the cultures,‘5 but the total colony numbers 
formed in response to the combinations of CSFs were less than 
the sum of the individual effects.** Therefore, most likely, the 
AML cell mass contains a spectrum of subsets of precursors 
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with variable growth factor reactivities that can be recruited 
into cell proliferation, depending on the exact combination of 
growth factors supplied. These AML cells may represent the 
neoplastic counterparts of normal marrow progenitors at more 
or less primitive stages of maturation exhibiting specific CSF 
requirements. 
From dose-effect studies with CSFs, a marked patient-to- 
patient variation with respect to growth factor responsiveness 
of AML cell proliferation has become apparent (Table 2). Thus 
different patterns of response can be distinguished among clin- 
ical cases. of AML. For instance, AML cell cycle activation 
can be achieved with any one of the four CSFs in certain cases 
of AML, whereas the cells of other patients respond to three 
or two factors only, or sometimes even to only one of the 
CSFs. These variations may provide indicators of classifying 
patients with biologically different disease and may prove to 
be of prognostic value. Generally, the categories of growth 
factor reactivity do not correlate with morphological classifi- 
cation of human AML, except in the rare cases of erythroleu- 
kemia that appeared especially sensitive to erythropoietin. AML 
progenitor immunophenotypes established as a parameter of 
precursor cell maturation did not show a relationship with in 
vitro growth factor dependence either. I4 
Table 2 
Frequency of Recombinant Hematopoietic Growth 
Factors Acting As Stimuli of Human AML Growth In 
Vitro 
IL-3 GM-CSF G-CSF M-CSF A=Y Ref. 
- 32148 28148 O/48 Colony formation 28 
- 16/20 - - Colony formation 27 
819 919 519 - Colony formation 15 
19125 16125 13125 4125 DNA synthesis 14 
(serum-free) 
7120 9120 6120 2120 Colony formation 14 
(serum-free) 
NOW: Ratios indicate quotients of positive responses and total number of 
cases examined. 
The biological basis of the heterogeneity of growth factor 
responsiveness in clinical AML is not clear. The abilities of 
the AML blasts to react to certain CSFs and not to others could 
reflect the physiological diversity of normal hematopoietic pro- 
genitors with respect to their susceptibility to the hematopoietic 
growth factors. In this sense, the diversity of response could 
indicate the selective increase of certain precursors that have 
accumulated as a result of the differentiation arrest. An alter- 
native hypothesis to explain these phenomena of growth factor 
responses is that variations of cell growth are expressions of 
the transformed status of the cells and that asynchronous mat- 
uration is associated with abnormalities (e.g., a loss) of growth 
factor regulation. As our understanding of specific differences 
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of growth factor regulation between discrete precursor cell 
stages even in normal hematopoietis is only beginning to emerge, 
it is impossible to distinguish between these two explanations 
at the present ime. 
Which features of AML growth determine the imbalance 
of growth between AML and the normal hematopoietic tissue, 
and why does AML at a certain stage outgrow the normal 
tissue? Evidence indicating that the overgrowth of AML in 
normal marrow is caused by specific regulatory abnormalities 
is still lacking. Preferential growth of AML cells could result 
from an extraordinary susceptibility to one of the hematopoietic 
growth factors, for example, due to an overexpression of re- 
ceptors or their permanent activation by structural receptor 
abnormalities. Generally, the susceptibility of human AML to 
IL-3, GM-CSF, or G-CSF22.24.26 and the density of GM-CSF 
receptors upon AML blasts are in the same order as for normal 
cells.49-51 For instance, GM-CSF acts optimally at concentra- 
tions of 1 to 5 ng/ml (40 to 200 U/ml, 60 to 300 pW.22,24 
AML blasts express comparatively low levels (8 to 100 sites 
per cell) of GM-CSF receptors.49.” 
Another possible way of conferring a growth advantage 
upon AML cells would be the creation of an autocrine loop of 
stimulation. RNA message of GM-CSF has been demonstrated 
in the blasts of certain cases of AMLWe91 Colony stimulating 
activity was demonstrated in supematants conditioned by AML 
cells. This activity could be neutralized by an anti-GM-CSF 
antibody. 92 These data provided evidence for the autocrine 
production and secretion of GM-CSF in human AML. Indeed, 
in certain cases, AML cells will form colonies in vitro in the 
absence of any exogenously supplemented growth stimulus. It 
remains questionable as to whether or not GM-CSF production 
and GM-CSF response truly reside in one and the same cell 
that both belong to the leukemic clone. 
Release of CSFs from monocytes,93 fibroblasts,94 and en- 
dothelial cells95-97 is normally induced by specific stimuli, e.g., 
tumor necrosis factor (TNF)97-W or interleukin- 1(IL- 1).94*95*‘oo 
A question that is not definitely settled is whether the synthesis 
and release of CSFs by AML cells is controlled by physiolog- 
ical regulators or if it is constitutive. It has become apparent 
that synthesis of GM-CSF by AML blasts can be induced 
following exposure of the cells to interleukin-1 alpha (IL-l 
alpha) or IL- 1 beta,‘O’ and that in certain cases spontaneous 
AML cell proliferation in vitro can be switched off not only 
by anti-GM-CSF antibody, but also with neutralizing anti-IL- 
1 antibody. As a matter of fact, GM-CSF elaboration from 
AML blasts and the resulting proliferative activity may be 
governed by similar inducers (e.g., IL- 1) as that in normal cell 
types. Thus, CSF release from AML blasts may be under 
regulatory control rather than constitutive. 
One could argue that a CSF-mediated autocrine process of 
stimulation of AML blasts is not a malignant feature of the 
cells, i.e., associated with their transformed status. Autocrine- 
mediated growth in hematopoietis not unusual and does not 
necessarily represent neoplastic alteration. For example, the 
production of IL-2 by T-lymphocytes and the stimulability of 
the same cells by this factor, or the synthesis of M-CSF by 
monocytes are physiological phenomena.93 Normal hemato- 
poietic blast cells have not been critically examined for this 
particular feature. 
Taken together, no experimental evidence has been ob- 
tained to explain why AML growth gains a selective advantage 
over normal hematopoietis. Obviously, aspects of cell-cell in- 
teractions and the susceptibility of progenitor cells to recom- 
binant inhibiting factors have not yet been critically evaluated 
in the context of the recombinant hematopoietic growth factors. 
E. Maturation 
Whereas the hematopoietic growth factors are highly active 
in triggering cell proliferation, they appear usually incapable 
of inducing maturation i  human AML blasts. Surface markers 
indicative of progressive myeloid maturation did not appear as 
the result of incubation of the cells with IL-3, GM-CSF, or G- 
CSF. 15*16.26 Only in rare instances do IL-3, GM-CSF, G-CSF, 
or M-CSF bring about morphological alterations that are in- 
dicative of monocytic or granulocytic maturation. ‘6.34 Thus, 
although the cells express surface receptors for these factors 
and their cell cycle status can be activated by these molecules, 
they are unable to proceed along the maturation pathway. These 
observations uggest an abnormality in the intracellular ma- 
chinery that follows growth factor receptor ligand binding. The 
inefficiency of these factors to induce maturation i  AML cells 
was only slightly improved when the factors were presented 
to the cells in vitro as complete cocktails of IL-3, GM-CSF, 
G-CSF, M-CSF, and EPO. 
Why are AML cells incompetent to mature to terminally 
differentiated granulocytic ells when exposed to the appro- 
priate growth factors? Obviously, the answer to this question 
is fundamental with respect o our understanding of neoplastic 
growth. As the cells are intact at the level of ligand receptor 
binding, one may assume that the defect preventing proper 
maturation resides further downstream in the cell and involves 
the signal transduction route. Why a normal hematopoietic 
progenitor cell that responds to growth factor activation is 
capable of mounting a sequential series of maturation events 
and why the leukemic cell is incapable of eliciting a similar 
response are unresolved and remain a main target of future 
research. 
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